The break-up of the late Adolf Merckle’s industrial empire gained pace on Thursday when the German entrepreneur’s family holding company launched a sales process for Ratiopharm, the world’s fourth-largest generic drugs maker.

VEM Vermögensverwaltung, Merckle’s main investment company, said detailed offer documents would be sent to potential bidders at the beginning of October.